Short-term outcomes of single port robotic hysterectomy with concomitant sacrocolpopexy
The Da Vinci single port (SP) robotic platform heralds a new era of minimally invasive surgery (MIS). It differs from traditional and single-site robotic surgery; three instruments and a camera are all operated by a single robotic arm. This platform is approved by the Food and Drug Administration for urologic and otolaryngologic procedures; it is not yet approved for gynecologic surgeries. Current experiences of SP gynecologic procedures are limited to case series performed in other countries. This is the first study to describe SP gynecologic surgeries performed within the United States. (Source: American Journal of Obste...
Source: American Journal of Obstetrics and Gynecology - March 21, 2024 Category: OBGYN Authors: S Ashmore, K Kenton, S Collins, J Geynisman-tan, C Lewicky-gaupp, H Nguyen, M Mueller Source Type: research

If it ’s a target, it’s a pan-cancer target: Tissue is not the issue
Historically, cancer has been classified and treated on the basis of its organ of origin (e.g., breast or colon or lung cancer), which is determined by light microscopy. However, light microscopy does not uncover the factors that drive tumor formation and progression. Understanding tumor drivers requires molecular technology, which has fortunately advanced at a remarkable rate over the last two decades. As a result, there are now multiple tissue-agnostic Food and Drug Administration (FDA) approvals for patients with cancer (Fig. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 21, 2024 Category: Cancer & Oncology Authors: Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, Scott M. Lippman, Razelle Kurzrock Tags: Controversy Source Type: research

Cancers, Vol. 16, Pages 1237: Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1
We report the regulation of PD-L1 by YY1 at the transcriptional, post-transcriptional, and post-translational levels, resulting in the restoration of CD8+ T cells’ anti-tumor functions. We have performed bioinformatic analyses to further explore the relationship between both YY1 and PD-L1 in cancer and to corroborate these findings. In addition to its regulation of PD-L1, YY1 has several other anti-cancer activities, such as the regulation of proliferation and cell viability, invasion, epithelial–mesenchymal transition (EMT), metastasis, and chemo-immuno-resistance. Thus, targeting YY1 will have...
Source: Cancers - March 21, 2024 Category: Cancer & Oncology Authors: Ana Dillen Indy Bui Megan Jung Stephanie Agioti Apostolos Zaravinos Benjamin Bonavida Tags: Review Source Type: research

Neurostimulation for Pediatric Obstructive Sleep Apnea
Up to 80% of children with Down syndrome (DS) are affected by obstructive sleep apnea (OSA), and only 16% to 30% will have resolution of their OSA with adenotonsillectomy. Hypoglossal nerve stimulation is a well-established therapy for adults with OSA and was recently approved by the Food and Drug Administration for use in children with DS and residual OSA. There is robust experience with this therapy in adults that has led to well-established care pathways. However, given the challenges inherent to caring for a complex pediatric population, these pathways are not directly transferrable to children with DS. (Source: Otolar...
Source: Otolaryngologic clinics of North America - March 21, 2024 Category: ENT & OMF Authors: Doug Chieffe, Christopher Hartnick Source Type: research

Development of a Machine-learning Based, Remote-Monitoring System for the Automated Detection of the Periodic Acoustic Signal Associated With the Bruit of an AV Access
The SmartPatch (Alio, Inc.) was cleared by the Food and Drug Administration (FDA) in March of 2023 as a wearable device to non-invasively assess heart rate, skin temperature, hemoglobin, hematocrit, and as a qualitative indicator of abnormal potassium levels. The device also has a microphone that is directly in contact with an arteriovenous (AV) access, simultaneously collecting a 15-second, reviewable acoustic recording of the AV access. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - March 20, 2024 Category: Surgery Authors: David R. Whittaker, Forrest Miller, Nell Shimasaki, Samit Gupta, David Kuraguntla Source Type: research

Antagonism of the Platelet-Activating Factor Pathway Mitigates Inflammatory Adverse Events Driven by Anti-erythrocyte Antibody Therapy in Mice
J Immunol. 2024 Mar 20:ji2300638. doi: 10.4049/jimmunol.2300638. Online ahead of print.ABSTRACTImmune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts primarily due to antiplatelet autoantibodies. Anti-D is a donor-derived polyclonal Ab against the rhesus D Ag on erythrocytes used to treat ITP. Unfortunately, adverse inflammatory/hypersensitivity reactions and a Food and Drug Administration-issued black box warning have limited its clinical use. This underscores the imperative to understand the inflammatory pathway associated with anti-erythrocyte Ab-based therapies. TER119 is an erythro...
Source: Journal of Immunology - March 20, 2024 Category: Allergy & Immunology Authors: Kevin Doyoon Won Lazaro Gil Gonzalez Yoelys Cruz-Leal Alequis Pavon Oro Alan H Lazarus Source Type: research

Antagonism of the Platelet-Activating Factor Pathway Mitigates Inflammatory Adverse Events Driven by Anti-erythrocyte Antibody Therapy in Mice
J Immunol. 2024 Mar 20:ji2300638. doi: 10.4049/jimmunol.2300638. Online ahead of print.ABSTRACTImmune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts primarily due to antiplatelet autoantibodies. Anti-D is a donor-derived polyclonal Ab against the rhesus D Ag on erythrocytes used to treat ITP. Unfortunately, adverse inflammatory/hypersensitivity reactions and a Food and Drug Administration-issued black box warning have limited its clinical use. This underscores the imperative to understand the inflammatory pathway associated with anti-erythrocyte Ab-based therapies. TER119 is an erythro...
Source: Journal of Immunology - March 20, 2024 Category: Allergy & Immunology Authors: Kevin Doyoon Won Lazaro Gil Gonzalez Yoelys Cruz-Leal Alequis Pavon Oro Alan H Lazarus Source Type: research

Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy
Clin Ther. 2024 Mar 19:S0149-2918(24)00062-6. doi: 10.1016/j.clinthera.2024.02.007. Online ahead of print.ABSTRACTPURPOSE: Hypertrophic cardiomyopathy (HCM) is an under-recognized genetic cardiac disorder affecting the muscles and contractility of the heart, which in turn can result in heart failure symptoms, arrhythmia, and sudden cardiac death. Previously, pharmacotherapy options for HCM were not disease-specific, often poorly tolerated, and overall inadequate for optimal management. This narrative review discusses the pharmacology of the novel drug mavacamten, the clinical trials supporting its use, and considerations f...
Source: Clinical Therapeutics - March 20, 2024 Category: Drugs & Pharmacology Authors: J Chase Cole Samantha F Benvie Marci DeLosSantos Source Type: research

Antagonism of the Platelet-Activating Factor Pathway Mitigates Inflammatory Adverse Events Driven by Anti-erythrocyte Antibody Therapy in Mice
J Immunol. 2024 Mar 20:ji2300638. doi: 10.4049/jimmunol.2300638. Online ahead of print.ABSTRACTImmune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts primarily due to antiplatelet autoantibodies. Anti-D is a donor-derived polyclonal Ab against the rhesus D Ag on erythrocytes used to treat ITP. Unfortunately, adverse inflammatory/hypersensitivity reactions and a Food and Drug Administration-issued black box warning have limited its clinical use. This underscores the imperative to understand the inflammatory pathway associated with anti-erythrocyte Ab-based therapies. TER119 is an erythro...
Source: Journal of Immunology - March 20, 2024 Category: Allergy & Immunology Authors: Kevin Doyoon Won Lazaro Gil Gonzalez Yoelys Cruz-Leal Alequis Pavon Oro Alan H Lazarus Source Type: research

Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy
Clin Ther. 2024 Mar 19:S0149-2918(24)00062-6. doi: 10.1016/j.clinthera.2024.02.007. Online ahead of print.ABSTRACTPURPOSE: Hypertrophic cardiomyopathy (HCM) is an under-recognized genetic cardiac disorder affecting the muscles and contractility of the heart, which in turn can result in heart failure symptoms, arrhythmia, and sudden cardiac death. Previously, pharmacotherapy options for HCM were not disease-specific, often poorly tolerated, and overall inadequate for optimal management. This narrative review discusses the pharmacology of the novel drug mavacamten, the clinical trials supporting its use, and considerations f...
Source: Clinical Therapeutics - March 20, 2024 Category: Drugs & Pharmacology Authors: J Chase Cole Samantha F Benvie Marci DeLosSantos Source Type: research

Bacteroides and NAFLD: pathophysiology and therapy
Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition observed globally, with the potential to progress to non-alcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular carcinoma. Currently, the US Food and Drug Administration (FDA) has not approved any drugs for the treatment of NAFLD. NAFLD is characterized by histopathological abnormalities in the liver, such as lipid accumulation, steatosis, hepatic balloon degeneration, and inflammation. Dysbiosis of the gut microbiota and its metabolites significantly contribute to the initiation and advancement of NAFLD. Bacteroides, a potential...
Source: Frontiers in Microbiology - March 20, 2024 Category: Microbiology Source Type: research

Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents
Expert Rev Neurother. 2024 Mar 19:1-13. doi: 10.1080/14737175.2024.2327533. Online ahead of print.ABSTRACTINTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention and/or hyperactivity and impulsivity. Viloxazine extended-release (ER) capsules (Qelbree®) is a US Food and Drug Administration-approved nonstimulant treatment option for children, adolescents, and adults with ADHD.AREAS COVERED: This review manuscript summarizes the neurobiology of ADHD and currently available treatment options before discussing viloxazine pharmacology, efficacy, safety, and tol...
Source: Expert Review of Neurotherapeutics - March 19, 2024 Category: Neurology Authors: Vladimir Maletic Gregory W Mattingly Jami Earnest Source Type: research

Riboflavin protects against pancreatic cancer metastasis by targeting TGF- β receptor 1
Bioorg Chem. 2024 Mar 16;146:107274. doi: 10.1016/j.bioorg.2024.107274. Online ahead of print.ABSTRACTThe inhibition of transforming growth factor-β1 (TGF-β1) signaling by targeting TGF-β receptor 1 (TβR1) has been considered as an ideal approach for the prevention of pancreatic cancer metastasis. Utilizing a pharmacophore model for TβR1 inhibitors, candidate compounds with the potential TβR1 binding ability were screened from the U.S. Food and Drug Administration (FDA) database, and riboflavin (RF) with a highest fit value was chosen to investigate its binding ability to TβR1 and effect on TGF-β1 signaling in panc...
Source: Bioorganic Chemistry - March 19, 2024 Category: Chemistry Authors: Juanping Zhao Xiaofeng Liu Xinxin Jin Tianyi Dong Xiong Gao Jian Wang Yanchun Li Enlong Ma Source Type: research

Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents
Expert Rev Neurother. 2024 Mar 19:1-13. doi: 10.1080/14737175.2024.2327533. Online ahead of print.ABSTRACTINTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention and/or hyperactivity and impulsivity. Viloxazine extended-release (ER) capsules (Qelbree®) is a US Food and Drug Administration-approved nonstimulant treatment option for children, adolescents, and adults with ADHD.AREAS COVERED: This review manuscript summarizes the neurobiology of ADHD and currently available treatment options before discussing viloxazine pharmacology, efficacy, safety, and tol...
Source: Expert Review of Neurotherapeutics - March 19, 2024 Category: Neurology Authors: Vladimir Maletic Gregory W Mattingly Jami Earnest Source Type: research